We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases.
- Authors
Tokito, Takaaki; Shukuya, Takehito; Akamatsu, Hiroaki; Taira, Tetsuhiko; Ono, Akira; Kenmotsu, Hirotsugu; Naito, Tateaki; Murakami, Haruyasu; Takahashi, Toshiaki; Endo, Masahiro; Yamamoto, Nobuyuki
- Abstract
Purpose: Skeletal-related events (SREs) negatively affect the quality of life of patients with cancer. Vascular endothelial growth factor receptor (VEGFR)-targeted therapy is effective against bone metastasis in animal models, but the clinical efficacy of anti-VEGFR inhibitors against bone metastases remains unclear. Therefore, we aimed to investigate the efficacy of chemotherapy with bevacizumab, an anti-VEGF antibody, against bone metastases. Methods: We retrospectively reviewed consecutive patients with non-squamous non-small cell lung cancer who received first-line platinum-based chemotherapy with zoledronic acid at Shizuoka Cancer Center between 2007 and 2011. Results: Of 25 patients, 13 received bevacizumab-based chemotherapy (BEV group) and 12 received chemotherapy without bevacizumab (non-BEV group). The overall response (54 vs. 8 %, p = 0.01) and disease control (100 vs. 50 %, p = 0.01) rates were higher in the BEV group than in the non-BEV group. The bone-specific response (23 vs. 0 %, p = 0.038) and disease control (100 vs. 67 %, p = 0.01) rates were also higher in the BEV group. The median time to progression (TTP) for bone metastases was higher in the BEV group (13.7 vs. 4.3 months, p = 0.06), whereas that for overall disease was similar between the groups (5.7 vs. 2.6 months, p = 0.17). The proportions of patients with SREs were 23 and 50 % in the BEV and non-BEV groups, respectively ( p = 0.16). Conclusion: Bevacizumab might potentiate the antitumor activity of chemotherapy against systemic disease and bone metastases, prolonging bone-specific TTP and reducing the incidence of SRE.
- Subjects
LUNG cancer treatment; CANCER chemotherapy; BONE metastasis; VASCULAR endothelial growth factor receptors; BEVACIZUMAB; IMMUNOGLOBULINS; QUALITY of life
- Publication
Cancer Chemotherapy & Pharmacology, 2013, Vol 71, Issue 6, p1493
- ISSN
0344-5704
- Publication type
Article
- DOI
10.1007/s00280-013-2148-3